We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Read MoreHide Full Article
Key Takeaways
Haemonetics' Plasma franchise returned to growth, with fiscal Q4 revenues rising 3% to $130 million.
HAE's NexSys PCS system is seeing strong uptake and is expected to support future growth.
Haemonetics faces concerns from $1.22B in long-term debt and intense manual and automated competition.
Haemonetics Corporation’s (HAE - Free Report) impressive Plasma franchise is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth. However, a debt-burdened balance sheet and fierce competitive pressure remain concerns for HAE’s operations.
In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 2.4% compared with the industry’s decline of 29.5%. The S&P 500 composite has grown 22.8% in the same time frame.
The global provider of blood and plasma supplies and services has a market capitalization of $2.82 billion. HAE beat on earnings in each of the trailing four quarters, delivering an average surprise of 6.6%.
Let us delve deeper.
Haemonetics’ Key Upsides
Potential Growth Drivers for the Plasma Franchise: Haemonetics’ Plasma business unit focuses on the collection of source plasma for pharmaceutical manufacturers using apheresis devices that only collect plasma. In fiscal 2025, Haemonetics signed new long-term agreements with BioLife and Grifols, reinforcing its continued close partnership and highlighting its ability to bring innovation to plasma collections.
In the fourth quarter of fiscal 2026, the Plasma franchise returned to growth with revenues of $130 million, up 3% on a reported basis and 13% on an organic basis (excluding CSL). Plasma momentum continued with growth driven by category leadership, differentiated innovation, and strong market fundamentals. Its share of U.S. plasma collections grew in the high single digits in fiscal 2026, along with double-digit growth in Europe.
NexSys PCS System Continues to Thrive: Haemonetics’ FDA-cleared, NexSys PCS (plasma collection system) is designed to increase plasma yield collections, improve productivity in customers’ centers, enhance the overall donor experience and provide safe and reliable collections that will become life-changing medicines for patients. Haemonetics received 510(k) clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology. The company’s full transition from the PCS2 devices to the latest NexSys with Persona Technology should drive meaningful improvements in the upcoming quarters.
Image Source: Zacks Investment Research
Haemonetics’ Key Downsides
Weak Solvency: Haemonetics exited the fiscal fourth quarter with cash and cash equivalents of $245.4 million and short-term debt & current maturities of $5 million on its balance sheet. The long-term debt at the end of the fiscal fourth quarter was $1.22 billion, indicating a highly leveraged balance sheet. Debt-to-capital ratio was 50.2%, while times interest earned ratio was 5.5 at the quarter’s end, down 5.5 sequentially.
Competitive Landscape: Haemonetics operates in a very competitive environment, both for manual and automated systems. Slower-than-expected product adoption by customers, especially the American Red Cross, might reduce the company’s revenues and profit.
HAE’s Estimate Trend
The Zacks Consensus Estimate for fiscal 2026 earnings has moved south 1 cent to $5.22 per share in the past 30 days.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $1.40 billion, which indicates a 4.9% decrease from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.
View the Zacks #1 Rank List
Image: Bigstock
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Key Takeaways
Haemonetics Corporation’s (HAE - Free Report) impressive Plasma franchise is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth. However, a debt-burdened balance sheet and fierce competitive pressure remain concerns for HAE’s operations.
In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 2.4% compared with the industry’s decline of 29.5%. The S&P 500 composite has grown 22.8% in the same time frame.
The global provider of blood and plasma supplies and services has a market capitalization of $2.82 billion. HAE beat on earnings in each of the trailing four quarters, delivering an average surprise of 6.6%.
Let us delve deeper.
Haemonetics’ Key Upsides
Potential Growth Drivers for the Plasma Franchise: Haemonetics’ Plasma business unit focuses on the collection of source plasma for pharmaceutical manufacturers using apheresis devices that only collect plasma. In fiscal 2025, Haemonetics signed new long-term agreements with BioLife and Grifols, reinforcing its continued close partnership and highlighting its ability to bring innovation to plasma collections.
In the fourth quarter of fiscal 2026, the Plasma franchise returned to growth with revenues of $130 million, up 3% on a reported basis and 13% on an organic basis (excluding CSL). Plasma momentum continued with growth driven by category leadership, differentiated innovation, and strong market fundamentals. Its share of U.S. plasma collections grew in the high single digits in fiscal 2026, along with double-digit growth in Europe.
NexSys PCS System Continues to Thrive: Haemonetics’ FDA-cleared, NexSys PCS (plasma collection system) is designed to increase plasma yield collections, improve productivity in customers’ centers, enhance the overall donor experience and provide safe and reliable collections that will become life-changing medicines for patients. Haemonetics received 510(k) clearance for the NexSys PCS Plasma Collection System with Persona PLUS technology. The company’s full transition from the PCS2 devices to the latest NexSys with Persona Technology should drive meaningful improvements in the upcoming quarters.
Image Source: Zacks Investment Research
Haemonetics’ Key Downsides
Weak Solvency: Haemonetics exited the fiscal fourth quarter with cash and cash equivalents of $245.4 million and short-term debt & current maturities of $5 million on its balance sheet. The long-term debt at the end of the fiscal fourth quarter was $1.22 billion, indicating a highly leveraged balance sheet. Debt-to-capital ratio was 50.2%, while times interest earned ratio was 5.5 at the quarter’s end, down 5.5 sequentially.
Competitive Landscape: Haemonetics operates in a very competitive environment, both for manual and automated systems. Slower-than-expected product adoption by customers, especially the American Red Cross, might reduce the company’s revenues and profit.
HAE’s Estimate Trend
The Zacks Consensus Estimate for fiscal 2026 earnings has moved south 1 cent to $5.22 per share in the past 30 days.
The Zacks Consensus Estimate for fiscal 2026 revenues is pegged at $1.40 billion, which indicates a 4.9% decrease from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Integra LifeSciences (IART - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 5.5%, well ahead of the industry’s negative 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, the average surprise being 26.3%. The company’s shares have rallied 43.8% against the industry’s 4.8% decline over the past year.
GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Integra LifeSciences, carrying a Zacks Rank #2 at present, has an earnings yield of 16% against the industry’s negative 3% yield. Shares of the company have gained 22.8% compared with the industry’s 4.8% growth. IART’s earnings topped estimates in each of the trailing four quarters, the average surprise being 16.8%.
Phibro Animal Health, carrying a Zacks Rank #2 at present, has an earnings yield of 9.2% compared with the industry’s 2.8% yield. Shares of the company have climbed 43.1% against the industry’s 27.9% decline. PAHC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.3%.